Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. Beats on EPS, Stock Down 4.59%

Aurinia Pharmaceuticals reported a small earnings beat on EPS, but there was no revenue reported. The stock reacted negatively, dropping 4.59%, which may indicate investor concerns despite the EPS surprise. The lack of guidance and additional context from management may have contributed to the stock's decline.